Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Moberg Pharma AB (publ) is a Swedish pharmaceutical company specializing in the development and commercialization of proprietary medical products based on proven substances. It primarily focuses on consumer healthcare solutions that address pain relief and skin conditions, with a strong emphasis on treating onychomycosis, commonly known as nail fungus. The company's flagship product, MOB-015, marketed under the Terclara brand, represents a novel topical treatment designed for effective delivery to the nail bed. Operating as a single segment dedicated to medical product innovation, Moberg Pharma targets markets across Europe, the Americas, and the rest of the world. Founded in 2006 and headquartered in Bromma, Sweden, the firm employs a small team of around 6-9 professionals and maintains a debt-free balance sheet with a focus on research-driven growth. In the healthcare sector, particularly within pharmaceuticals and biotechnology, Moberg Pharma plays a niche role by advancing accessible treatments for dermatological issues, contributing to improved patient outcomes in underserved areas of topical therapies.
kr 0.81
kr 0.07 (-8.14%)
Live · 10:45 PM · Twelve Data
The business is unprofitable at the operating level (-206.80% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 38.0% YoY with margins expanding 3104.7pp.
Negative free cash flow of -kr 61M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
kr 15M
▲ +38.0% YoY
Net Income (TTM)
-kr 26M
▲ +89.3% YoY
Op. Margin
-171.63%
▲ +3104.7pp YoY
ROIC
-3.26%
▲ +36.0pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-kr 45M
▲ +32.6% YoY
Op. Cash Flow (TTM)
-kr 17M
▲ +75.1% YoY
Net Debt
-kr 228M
Net Cash Position
Cash & Equiv.
kr 230M
3Y CAGR: +302.9%
Continue Research
Moberg Pharma AB (publ) (MOB.XSTO)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Moberg Pharma AB (publ) scores 40/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Moberg Pharma AB (publ) scores 40 out of 100 on Intrinsiqq's quality score, passing 3 of 6 checks, which makes it a mixed business on these measures. Recent fundamentals include a -171.6% operating margin and a -3.3% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full check-by-check breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh MOB.XSTO's valuation and scores 40/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.